Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus
2007

Testing New Methods for Diagnosing Lupus

Sample size: 48 publication 10 minutes Evidence: high

Author Information

Author(s): Mahler Michael, Waka Aderajew, Hiepe F, Fritzler Marvin J

Primary Institution: Charité-University of Medicine Berlin

Hypothesis

The study aims to evaluate the clinical accuracy of anti-SmD1 and anti-SmD3 ELISAs for detecting anti-Sm antibodies in systemic lupus erythematosus patients.

Conclusion

Both SmD peptide ELISAs are accurate assays for detecting anti-Sm antibodies, with the cut-off value significantly affecting their sensitivity and specificity.

Supporting Evidence

  • The study found a high degree of concordance between the two tests at an optimized cut-off value.
  • Both assays showed similar sensitivity and specificity when the cut-off was adjusted.
  • Anti-Sm antibodies are considered a specific but not very sensitive marker for systemic lupus erythematosus.

Takeaway

The study tested two methods to find out how well they can detect a specific type of antibody in people with lupus, and found that both methods work well when using the right settings.

Methodology

The study analyzed serum samples from lupus patients and controls using two different ELISA tests for anti-Sm antibodies.

Potential Biases

Potential bias in sample selection as the cohorts were preselected based on positive anti-Sm results.

Limitations

The study's findings may not be generalizable to all populations due to the specific cohorts used.

Participant Demographics

Participants included 48 systemic lupus erythematosus patients and 99 controls with various autoimmune diseases.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1186/ar2266

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication